Non‐invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146 958 pregnancies

ABSTRACT Objectives To report the clinical performance of massively parallel sequencing‐based non‐invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over 140 000 clinical samples and to compare its performance in low‐risk and high‐risk pregnancies. Methods Between 1 January 201...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ultrasound in obstetrics & gynecology Ročník 45; číslo 5; s. 530 - 538
Hlavní autoři: Zhang, H., Gao, Y., Jiang, F., Fu, M., Yuan, Y., Guo, Y., Zhu, Z., Lin, M., Liu, Q., Tian, Z., Chen, F., Lau, T. K., Zhao, L., Yi, X., Yin, Y., Wang, W.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Chichester, UK John Wiley & Sons, Ltd 01.05.2015
Wiley Subscription Services, Inc
Témata:
Adult
Cell-Free System
cell‐free DNA
China - epidemiology
Chromosome Disorders - diagnosis
Chromosome Disorders - embryology
Chromosome Disorders - genetics
Chromosomes, Human, Pair 13 - genetics
Chromosomes, Human, Pair 18 - genetics
clinical performance
CNV
DNA - genetics
DNA Methylation
Down Syndrome - diagnosis
Down Syndrome - embryology
Down Syndrome - genetics
false negative
false positive
Female
Follow-Up Studies
Genetic Testing - methods
Humans
Infant, Newborn
low‐risk population
Maternal Serum Screening Tests
mosaicism
NIPT
Pregnancy
Pregnancy Outcome
Prenatal Diagnosis
Reproducibility of Results
trisomy
Trisomy - diagnosis
Trisomy - genetics
Trisomy 13 Syndrome
Trisomy 18 Syndrome
China
false negative
clinical performance
mosaicism
cell-free DNA
CNV
NIPT
low-risk population
trisomy
false positive
ISSN:0960-7692, 1469-0705, 1469-0705
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract ABSTRACT Objectives To report the clinical performance of massively parallel sequencing‐based non‐invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over 140 000 clinical samples and to compare its performance in low‐risk and high‐risk pregnancies. Methods Between 1 January 2012 and 31 August 2013, 147 314 NIPT requests to screen for fetal trisomies 21, 18 and 13 using low‐coverage whole‐genome sequencing of plasma cell‐free DNA were received. The results were validated by karyotyping or follow‐up of clinical outcomes. Results NIPT was performed and results obtained in 146 958 samples, for which outcome data were available in 112 669 (76.7%). Repeat blood sampling was required in 3213 cases and 145 had test failure. Aneuploidy was confirmed in 720/781 cases positive for trisomy 21, 167/218 cases positive for trisomy 18 and 22/67 cases positive for trisomy 13 on NIPT. Nine false negatives were identified, including six cases of trisomy 21 and three of trisomy 18. The overall sensitivity of NIPT was 99.17%, 98.24% and 100% for trisomies 21, 18 and 13, respectively, and specificity was 99.95%, 99.95% and 99.96% for trisomies 21, 18 and 13, respectively. There was no significant difference in test performance between the 72 382 high‐risk and 40 287 low‐risk subjects (sensitivity, 99.21% vs 98.97% (P = 0.82); specificity, 99.95% vs 99.95% (P = 0.98)). The major factors contributing to false‐positive and false‐negative NIPT results were maternal copy number variant and fetal/placental mosaicism, but fetal fraction had no effect. Conclusions Using a stringent protocol, the good performance of NIPT shown by early validation studies can be maintained in large clinical samples. This technique can provide equally high sensitivity and specificity in screening for trisomy 21 in a low‐risk, as compared to high‐risk, population. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd. Linked Comment: Ultrasound Obstet Gynecol 2015; 45: 512–513
AbstractList To report the clinical performance of massively parallel sequencing-based non-invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over 140,000 clinical samples and to compare its performance in low-risk and high-risk pregnancies.OBJECTIVESTo report the clinical performance of massively parallel sequencing-based non-invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over 140,000 clinical samples and to compare its performance in low-risk and high-risk pregnancies.Between 1 January 2012 and 31 August 2013, 147,314 NIPT requests to screen for fetal trisomies 21, 18 and 13 using low-coverage whole-genome sequencing of plasma cell-free DNA were received. The results were validated by karyotyping or follow-up of clinical outcomes.METHODSBetween 1 January 2012 and 31 August 2013, 147,314 NIPT requests to screen for fetal trisomies 21, 18 and 13 using low-coverage whole-genome sequencing of plasma cell-free DNA were received. The results were validated by karyotyping or follow-up of clinical outcomes.NIPT was performed and results obtained in 146,958 samples, for which outcome data were available in 112,669 (76.7%). Repeat blood sampling was required in 3213 cases and 145 had test failure. Aneuploidy was confirmed in 720/781 cases positive for trisomy 21, 167/218 cases positive for trisomy 18 and 22/67 cases positive for trisomy 13 on NIPT. Nine false negatives were identified, including six cases of trisomy 21 and three of trisomy 18. The overall sensitivity of NIPT was 99.17%, 98.24% and 100% for trisomies 21, 18 and 13, respectively, and specificity was 99.95%, 99.95% and 99.96% for trisomies 21, 18 and 13, respectively. There was no significant difference in test performance between the 72,382 high-risk and 40,287 low-risk subjects (sensitivity, 99.21% vs. 98.97% (P = 0.82); specificity, 99.95% vs. 99.95% (P = 0.98)). The major factors contributing to false-positive and false-negative NIPT results were maternal copy number variant and fetal/placental mosaicism, but fetal fraction had no effect.RESULTSNIPT was performed and results obtained in 146,958 samples, for which outcome data were available in 112,669 (76.7%). Repeat blood sampling was required in 3213 cases and 145 had test failure. Aneuploidy was confirmed in 720/781 cases positive for trisomy 21, 167/218 cases positive for trisomy 18 and 22/67 cases positive for trisomy 13 on NIPT. Nine false negatives were identified, including six cases of trisomy 21 and three of trisomy 18. The overall sensitivity of NIPT was 99.17%, 98.24% and 100% for trisomies 21, 18 and 13, respectively, and specificity was 99.95%, 99.95% and 99.96% for trisomies 21, 18 and 13, respectively. There was no significant difference in test performance between the 72,382 high-risk and 40,287 low-risk subjects (sensitivity, 99.21% vs. 98.97% (P = 0.82); specificity, 99.95% vs. 99.95% (P = 0.98)). The major factors contributing to false-positive and false-negative NIPT results were maternal copy number variant and fetal/placental mosaicism, but fetal fraction had no effect.Using a stringent protocol, the good performance of NIPT shown by early validation studies can be maintained in large clinical samples. This technique can provide equally high sensitivity and specificity in screening for trisomy 21 in a low-risk, as compared to high-risk, population.CONCLUSIONSUsing a stringent protocol, the good performance of NIPT shown by early validation studies can be maintained in large clinical samples. This technique can provide equally high sensitivity and specificity in screening for trisomy 21 in a low-risk, as compared to high-risk, population.
ABSTRACT Objectives To report the clinical performance of massively parallel sequencing‐based non‐invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over 140 000 clinical samples and to compare its performance in low‐risk and high‐risk pregnancies. Methods Between 1 January 2012 and 31 August 2013, 147 314 NIPT requests to screen for fetal trisomies 21, 18 and 13 using low‐coverage whole‐genome sequencing of plasma cell‐free DNA were received. The results were validated by karyotyping or follow‐up of clinical outcomes. Results NIPT was performed and results obtained in 146 958 samples, for which outcome data were available in 112 669 (76.7%). Repeat blood sampling was required in 3213 cases and 145 had test failure. Aneuploidy was confirmed in 720/781 cases positive for trisomy 21, 167/218 cases positive for trisomy 18 and 22/67 cases positive for trisomy 13 on NIPT. Nine false negatives were identified, including six cases of trisomy 21 and three of trisomy 18. The overall sensitivity of NIPT was 99.17%, 98.24% and 100% for trisomies 21, 18 and 13, respectively, and specificity was 99.95%, 99.95% and 99.96% for trisomies 21, 18 and 13, respectively. There was no significant difference in test performance between the 72 382 high‐risk and 40 287 low‐risk subjects (sensitivity, 99.21% vs 98.97% (P = 0.82); specificity, 99.95% vs 99.95% (P = 0.98)). The major factors contributing to false‐positive and false‐negative NIPT results were maternal copy number variant and fetal/placental mosaicism, but fetal fraction had no effect. Conclusions Using a stringent protocol, the good performance of NIPT shown by early validation studies can be maintained in large clinical samples. This technique can provide equally high sensitivity and specificity in screening for trisomy 21 in a low‐risk, as compared to high‐risk, population. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd. Linked Comment: Ultrasound Obstet Gynecol 2015; 45: 512–513
Objectives To report the clinical performance of massively parallel sequencing-based non-invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over 140000 clinical samples and to compare its performance in low-risk and high-risk pregnancies. Methods Between 1 January 2012 and 31 August 2013, 147314 NIPT requests to screen for fetal trisomies 21, 18 and 13 using low-coverage whole-genome sequencing of plasma cell-free DNA were received. The results were validated by karyotyping or follow-up of clinical outcomes. Results NIPT was performed and results obtained in 146958 samples, for which outcome data were available in 112669 (76.7%). Repeat blood sampling was required in 3213 cases and 145 had test failure. Aneuploidy was confirmed in 720/781 cases positive for trisomy 21, 167/218 cases positive for trisomy 18 and 22/67 cases positive for trisomy 13 on NIPT. Nine false negatives were identified, including six cases of trisomy 21 and three of trisomy 18. The overall sensitivity of NIPT was 99.17%, 98.24% and 100% for trisomies 21, 18 and 13, respectively, and specificity was 99.95%, 99.95% and 99.96% for trisomies 21, 18 and 13, respectively. There was no significant difference in test performance between the 72382 high-risk and 40287 low-risk subjects (sensitivity, 99.21% vs 98.97% (P=0.82); specificity, 99.95% vs 99.95% (P=0.98)). The major factors contributing to false-positive and false-negative NIPT results were maternal copy number variant and fetal/placental mosaicism, but fetal fraction had no effect. Conclusions Using a stringent protocol, the good performance of NIPT shown by early validation studies can be maintained in large clinical samples. This technique can provide equally high sensitivity and specificity in screening for trisomy 21 in a low-risk, as compared to high-risk, population. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd. Linked Comment: Ultrasound Obstet Gynecol 2015; 45: 512-513
To report the clinical performance of massively parallel sequencing-based non-invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over 140,000 clinical samples and to compare its performance in low-risk and high-risk pregnancies. Between 1 January 2012 and 31 August 2013, 147,314 NIPT requests to screen for fetal trisomies 21, 18 and 13 using low-coverage whole-genome sequencing of plasma cell-free DNA were received. The results were validated by karyotyping or follow-up of clinical outcomes. NIPT was performed and results obtained in 146,958 samples, for which outcome data were available in 112,669 (76.7%). Repeat blood sampling was required in 3213 cases and 145 had test failure. Aneuploidy was confirmed in 720/781 cases positive for trisomy 21, 167/218 cases positive for trisomy 18 and 22/67 cases positive for trisomy 13 on NIPT. Nine false negatives were identified, including six cases of trisomy 21 and three of trisomy 18. The overall sensitivity of NIPT was 99.17%, 98.24% and 100% for trisomies 21, 18 and 13, respectively, and specificity was 99.95%, 99.95% and 99.96% for trisomies 21, 18 and 13, respectively. There was no significant difference in test performance between the 72,382 high-risk and 40,287 low-risk subjects (sensitivity, 99.21% vs. 98.97% (P = 0.82); specificity, 99.95% vs. 99.95% (P = 0.98)). The major factors contributing to false-positive and false-negative NIPT results were maternal copy number variant and fetal/placental mosaicism, but fetal fraction had no effect. Using a stringent protocol, the good performance of NIPT shown by early validation studies can be maintained in large clinical samples. This technique can provide equally high sensitivity and specificity in screening for trisomy 21 in a low-risk, as compared to high-risk, population.
Linked Comment: Ultrasound Obstet Gynecol 2015; 45: 512–513
Objectives To report the clinical performance of massively parallel sequencing-based non-invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over 140000 clinical samples and to compare its performance in low-risk and high-risk pregnancies. Methods Between 1 January 2012 and 31 August 2013, 147314 NIPT requests to screen for fetal trisomies 21, 18 and 13 using low-coverage whole-genome sequencing of plasma cell-free DNA were received. The results were validated by karyotyping or follow-up of clinical outcomes. Results NIPT was performed and results obtained in 146958 samples, for which outcome data were available in 112669 (76.7%). Repeat blood sampling was required in 3213 cases and 145 had test failure. Aneuploidy was confirmed in 720/781 cases positive for trisomy 21, 167/218 cases positive for trisomy 18 and 22/67 cases positive for trisomy 13 on NIPT. Nine false negatives were identified, including six cases of trisomy 21 and three of trisomy 18. The overall sensitivity of NIPT was 99.17%, 98.24% and 100% for trisomies 21, 18 and 13, respectively, and specificity was 99.95%, 99.95% and 99.96% for trisomies 21, 18 and 13, respectively. There was no significant difference in test performance between the 72382 high-risk and 40287 low-risk subjects (sensitivity, 99.21% vs 98.97% ( P =0.82); specificity, 99.95% vs 99.95% ( P =0.98)). The major factors contributing to false-positive and false-negative NIPT results were maternal copy number variant and fetal/placental mosaicism, but fetal fraction had no effect. Conclusions Using a stringent protocol, the good performance of NIPT shown by early validation studies can be maintained in large clinical samples. This technique can provide equally high sensitivity and specificity in screening for trisomy 21 in a low-risk, as compared to high-risk, population. Copyright copyright 2015 ISUOG. Published by John Wiley & Sons Ltd. Linked Comment: Ultrasound Obstet Gynecol 2015; 45: 512-513
Author Zhu, Z.
Yi, X.
Liu, Q.
Jiang, F.
Gao, Y.
Lin, M.
Lau, T. K.
Tian, Z.
Yuan, Y.
Guo, Y.
Chen, F.
Wang, W.
Zhao, L.
Zhang, H.
Fu, M.
Yin, Y.
Author_xml – sequence: 1
  givenname: H.
  surname: Zhang
  fullname: Zhang, H.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 2
  givenname: Y.
  surname: Gao
  fullname: Gao, Y.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 3
  givenname: F.
  surname: Jiang
  fullname: Jiang, F.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 4
  givenname: M.
  surname: Fu
  fullname: Fu, M.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 5
  givenname: Y.
  surname: Yuan
  fullname: Yuan, Y.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 6
  givenname: Y.
  surname: Guo
  fullname: Guo, Y.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 7
  givenname: Z.
  surname: Zhu
  fullname: Zhu, Z.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 8
  givenname: M.
  surname: Lin
  fullname: Lin, M.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 9
  givenname: Q.
  surname: Liu
  fullname: Liu, Q.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 10
  givenname: Z.
  surname: Tian
  fullname: Tian, Z.
  organization: BGI Clinical Laboratories‐Tianjin
– sequence: 11
  givenname: H.
  surname: Zhang
  fullname: Zhang, H.
  organization: BGI Clinical Laboratories‐Wuhan
– sequence: 12
  givenname: F.
  surname: Chen
  fullname: Chen, F.
  organization: University of Copenhagen
– sequence: 13
  givenname: T. K.
  surname: Lau
  fullname: Lau, T. K.
  organization: Paramount Medical Centre
– sequence: 14
  givenname: L.
  surname: Zhao
  fullname: Zhao, L.
  organization: BGI Clinical Laboratories‐Shenzen
– sequence: 15
  givenname: X.
  surname: Yi
  fullname: Yi, X.
  organization: BGI‐Shenzen
– sequence: 16
  givenname: Y.
  surname: Yin
  fullname: Yin, Y.
  organization: BGI‐Shenzen
– sequence: 17
  givenname: W.
  surname: Wang
  fullname: Wang, W.
  organization: BGI Clinical Laboratories‐Shenzen
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25598039$$D View this record in MEDLINE/PubMed
BookMark eNqN0btOHDEUBmArIoLlUuQFkKU0RMqA7x7TIZRAJBQaqEdez5mV0Yy9sWe4dDwCz8iTxJuFFEhBqdx859c5_rfRRogBEPpEySElhB1NcXFIhTbsA5pRoUxFNJEbaEaMIpVWhm2h7ZxvCCFKcLWJtpiUpibczJD_GcPz45MPtzb7W8DLBMGOtscj5NGHBe5iwmPyOQ4eMmb0K6Y1tqHFlB9j1_vgXdFwv4TkITjAXYoDLltgI-tV3CLY4MrsLvrY2T7D3su7g66_f7s6Pa8uLs9-nJ5cVE7UmlXacOg6rlprQRttBUheEyOkllA76qiGuRSCCa6latVcStDCEsWE0461jO-gg3XuMsVfU7miGXx20Pc2QJxyQ1VNhFTMqP-gWkkjiVylfn5Db-KUQjlkpSRlnHJd1P6LmuYDtM0y-cGmh-b1vwv4sgYuxZwTdH8JJc2qy6Z02fzpstijN9b50Y4-hjFZ3783ced7ePh3dHN9ebae-A2Udays
CODEN UOGYFJ
CitedBy_id crossref_primary_10_1002_uog_16010
crossref_primary_10_1007_s11427_017_9344_7
crossref_primary_10_1080_14737159_2018_1489242
crossref_primary_10_1002_pd_5053
crossref_primary_10_1186_s12920_020_00751_8
crossref_primary_10_1002_uog_15964
crossref_primary_10_1016_j_ajog_2015_03_043
crossref_primary_10_1038_srep38359
crossref_primary_10_1002_uog_15845
crossref_primary_10_1080_14737159_2019_1562906
crossref_primary_10_1002_pd_5049
crossref_primary_10_1186_s13039_020_00523_0
crossref_primary_10_1002_pd_5603
crossref_primary_10_1371_journal_pone_0189235
crossref_primary_10_1002_pd_4758
crossref_primary_10_32388_N2VRUA_2
crossref_primary_10_1007_s10897_016_9934_0
crossref_primary_10_1007_s10897_018_0268_y
crossref_primary_10_3390_jpm13101468
crossref_primary_10_1002_ajmg_c_31675
crossref_primary_10_1080_23294515_2018_1469551
crossref_primary_10_3390_genes14030668
crossref_primary_10_1007_s11427_019_9600_0
crossref_primary_10_1136_bmjopen_2015_010002
crossref_primary_10_1007_s00404_023_07267_3
crossref_primary_10_1016_j_jgg_2018_10_001
crossref_primary_10_1186_s12967_019_1871_x
crossref_primary_10_1371_journal_pone_0156088
crossref_primary_10_1371_journal_pone_0159233
crossref_primary_10_1002_adfm_202211669
crossref_primary_10_1038_s41598_022_14049_5
crossref_primary_10_1371_journal_pone_0220979
crossref_primary_10_1186_s40246_019_0198_2
crossref_primary_10_1016_j_ejogrb_2017_09_025
crossref_primary_10_1177_2374373517720482
crossref_primary_10_1186_s13073_021_00836_8
crossref_primary_10_3389_fpubh_2025_1535381
crossref_primary_10_1002_uog_15749
crossref_primary_10_1002_jgm_3362
crossref_primary_10_1186_s12884_025_07992_4
crossref_primary_10_1080_14737159_2021_1911651
crossref_primary_10_1002_mgg3_1094
crossref_primary_10_1186_s40246_019_0250_2
crossref_primary_10_1111_1471_0528_14050
crossref_primary_10_1016_j_ajog_2017_10_005
crossref_primary_10_1016_j_rbmo_2023_04_005
crossref_primary_10_1186_s12920_019_0590_8
crossref_primary_10_2217_cer_2022_0088
crossref_primary_10_1002_uog_15733
crossref_primary_10_1002_uog_15975
crossref_primary_10_3389_fgene_2020_00624
crossref_primary_10_1002_pd_5260
crossref_primary_10_1002_pd_4841
crossref_primary_10_1056_NEJMra1705345
crossref_primary_10_1002_pd_4601
crossref_primary_10_1186_s12884_021_03570_6
crossref_primary_10_1002_pd_5014
crossref_primary_10_1002_pd_4608
crossref_primary_10_1016_j_cca_2023_117758
crossref_primary_10_1586_14737159_2015_1084227
crossref_primary_10_1002_mgg3_1232
crossref_primary_10_3390_jpm13010001
crossref_primary_10_1186_s12920_021_00941_y
crossref_primary_10_3390_jcm13144007
crossref_primary_10_1080_14767058_2019_1623779
crossref_primary_10_1055_a_2126_7476
crossref_primary_10_3390_diagnostics12010059
crossref_primary_10_1007_s00404_021_06203_7
crossref_primary_10_1080_14767058_2021_1949449
crossref_primary_10_1002_pd_4837
crossref_primary_10_1016_j_bpobgyn_2017_02_007
crossref_primary_10_3389_fgene_2020_570333
crossref_primary_10_1007_s10815_021_02351_6
crossref_primary_10_1155_2016_7397405
crossref_primary_10_1007_s00247_017_3958_y
crossref_primary_10_1093_nar_gkac638
crossref_primary_10_3389_fgene_2022_999587
crossref_primary_10_1371_journal_pone_0284493
crossref_primary_10_1016_j_ajogmf_2020_100232
crossref_primary_10_1002_pd_5111
crossref_primary_10_1186_s13584_016_0060_0
crossref_primary_10_1002_uog_20416
crossref_primary_10_1002_uog_17492
crossref_primary_10_1016_j_tjog_2017_08_020
crossref_primary_10_1097_MD_0000000000029985
crossref_primary_10_1002_uog_26311
crossref_primary_10_1007_s12611_016_0351_2
crossref_primary_10_1053_j_semperi_2015_11_003
crossref_primary_10_12688_f1000research_9215_1
crossref_primary_10_1016_j_ygeno_2022_110556
crossref_primary_10_1002_jcla_24870
crossref_primary_10_1002_pd_6312
crossref_primary_10_1002_pd_5223
crossref_primary_10_1186_s13039_019_0441_5
crossref_primary_10_1002_pd_5901
crossref_primary_10_1186_s13039_023_00656_y
crossref_primary_10_1080_01443615_2023_2204959
crossref_primary_10_1111_jcmm_14614
crossref_primary_10_1016_j_ejogrb_2016_02_042
crossref_primary_10_23736_S2724_606X_24_05530_1
crossref_primary_10_1016_j_jhep_2024_11_008
crossref_primary_10_1080_14767058_2023_2233662
crossref_primary_10_3390_jcm11164760
crossref_primary_10_1002_ajmg_a_37460
crossref_primary_10_3389_fgene_2022_864076
crossref_primary_10_1002_pd_5695
crossref_primary_10_1186_s13039_023_00643_3
crossref_primary_10_1002_pd_5334
crossref_primary_10_3389_fgene_2022_887176
crossref_primary_10_1002_pd_4805
crossref_primary_10_1002_pd_4804
crossref_primary_10_3390_ijms160614122
crossref_primary_10_1016_j_ejmg_2020_103895
crossref_primary_10_1002_pd_6307
crossref_primary_10_1097_AOG_0000000000001406
crossref_primary_10_1038_s41598_025_97230_w
crossref_primary_10_1016_j_gofs_2017_12_011
crossref_primary_10_1155_2015_926545
crossref_primary_10_1159_000435780
crossref_primary_10_1002_pd_6775
crossref_primary_10_1159_000501014
crossref_primary_10_1186_s12913_017_2618_0
crossref_primary_10_1080_10408363_2019_1631749
crossref_primary_10_1002_pd_5328
crossref_primary_10_1002_uog_15791
crossref_primary_10_1016_j_ejogrb_2020_11_026
crossref_primary_10_1155_2020_4712657
crossref_primary_10_1016_j_cca_2019_04_064
crossref_primary_10_1017_S0965539515000091
crossref_primary_10_1371_journal_pone_0329463
crossref_primary_10_1002_jcla_24660
crossref_primary_10_1016_j_ajogmf_2020_100152
crossref_primary_10_1515_jpm_2016_0031
crossref_primary_10_1038_s41598_019_44018_4
crossref_primary_10_1002_mgg3_1256
crossref_primary_10_7717_peerj_14400
crossref_primary_10_1097_MD_0000000000007114
crossref_primary_10_3389_fgene_2021_661884
crossref_primary_10_1016_j_ajog_2015_12_025
crossref_primary_10_1007_s10815_023_02881_1
crossref_primary_10_1016_j_cell_2018_08_016
crossref_primary_10_1053_j_semperi_2018_07_020
crossref_primary_10_1080_01443615_2023_2288226
crossref_primary_10_1016_j_labinv_2022_100043
crossref_primary_10_1186_s12884_020_03279_y
crossref_primary_10_1111_jog_14954
crossref_primary_10_1177_0300060517695008
crossref_primary_10_4103_SBVJ_SBVJ_45_25
crossref_primary_10_1080_14767058_2017_1330881
crossref_primary_10_1186_s12884_020_03270_7
crossref_primary_10_1016_j_tibtech_2018_11_001
crossref_primary_10_1111_aogs_13047
crossref_primary_10_1111_aogs_13842
crossref_primary_10_1097_CM9_0000000000001531
crossref_primary_10_1186_s12920_021_01039_1
crossref_primary_10_1371_journal_pone_0167130
crossref_primary_10_1016_j_ajog_2015_08_036
crossref_primary_10_1002_pd_5898
crossref_primary_10_1097_AOG_0000000000001051
crossref_primary_10_1186_s12884_022_04966_8
crossref_primary_10_1017_S0965539516000061
crossref_primary_10_1186_s13039_022_00607_z
crossref_primary_10_2147_IJWH_S547427
crossref_primary_10_1002_ccr3_6280
crossref_primary_10_1111_cge_12818
crossref_primary_10_1186_s13039_020_0476_7
crossref_primary_10_5937_jomb0_33513
crossref_primary_10_1002_ajmg_c_31505
crossref_primary_10_3389_fmed_2022_875588
crossref_primary_10_1186_s13039_020_00480_8
crossref_primary_10_3389_fgene_2024_1502287
crossref_primary_10_1038_s41431_018_0188_1
crossref_primary_10_1097_GCO_0000000000000254
crossref_primary_10_1542_neo_18_9_e522
crossref_primary_10_3389_fmed_2021_672211
crossref_primary_10_1016_j_ajog_2022_01_019
crossref_primary_10_1016_j_heliyon_2024_e33437
crossref_primary_10_1186_s12884_021_03918_y
crossref_primary_10_1177_1049732318796833
crossref_primary_10_1109_JBHI_2016_2608859
crossref_primary_10_12688_f1000research_8243_1
crossref_primary_10_1016_j_ajog_2016_02_038
crossref_primary_10_1002_pd_6858
crossref_primary_10_1080_01443615_2019_1680617
crossref_primary_10_1097_OGX_0000000000000342
crossref_primary_10_1016_j_cll_2016_01_015
crossref_primary_10_1016_j_jmoldx_2020_09_008
crossref_primary_10_1136_archdischild_2019_317031
crossref_primary_10_1080_14737159_2023_2193291
crossref_primary_10_1038_s41598_017_06828_2
crossref_primary_10_3389_fgene_2022_982508
crossref_primary_10_3389_fped_2022_812781
crossref_primary_10_1002_pd_5081
crossref_primary_10_1155_2022_7517112
crossref_primary_10_1038_s41598_025_10446_8
crossref_primary_10_3390_medicina58010079
crossref_primary_10_1002_uog_21904
crossref_primary_10_1089_dna_2017_4075
crossref_primary_10_1016_j_ejmg_2020_104001
crossref_primary_10_1002_mgg3_1185
crossref_primary_10_1016_j_ajog_2021_04_212
crossref_primary_10_1002_pd_5879
crossref_primary_10_1007_s00404_015_3794_y
crossref_primary_10_1016_j_gim_2022_03_019
crossref_primary_10_1111_1471_0528_14197
crossref_primary_10_1007_s13224_015_0718_5
crossref_primary_10_1016_j_mrrev_2021_108399
crossref_primary_10_1186_s12884_021_04044_5
crossref_primary_10_1097_AOG_0000000000001385
crossref_primary_10_1002_ijgo_15535
crossref_primary_10_1002_mgg3_674
crossref_primary_10_1002_pd_4775
crossref_primary_10_1080_09674845_2018_1468152
crossref_primary_10_1371_journal_pone_0207840
crossref_primary_10_1038_srep16106
crossref_primary_10_1002_pd_5508
crossref_primary_10_1007_s40556_017_0116_4
crossref_primary_10_3390_diagnostics11101837
crossref_primary_10_1002_pd_4659
crossref_primary_10_1016_j_ajog_2016_06_039
crossref_primary_10_1136_gocm_2024_000187
crossref_primary_10_1016_j_clinbiochem_2015_02_011
crossref_primary_10_1038_s41525_021_00247_z
crossref_primary_10_1111_jog_12982
crossref_primary_10_3390_medicina58101472
crossref_primary_10_1016_j_hlpt_2019_10_003
crossref_primary_10_1016_j_tjog_2017_12_017
crossref_primary_10_3390_jcm8091311
crossref_primary_10_1016_j_ajog_2016_01_003
crossref_primary_10_1371_journal_pone_0247164
crossref_primary_10_1002_mgg3_545
crossref_primary_10_1002_pd_6150
crossref_primary_10_1186_s12920_021_00955_6
crossref_primary_10_1016_j_jogc_2016_09_004
crossref_primary_10_1016_j_tjog_2018_10_032
crossref_primary_10_1038_s41598_024_73183_4
crossref_primary_10_1517_14712598_2015_1045873
crossref_primary_10_1002_pd_6029
crossref_primary_10_2147_IJWH_S337249
crossref_primary_10_1007_s40556_017_0143_1
crossref_primary_10_1002_pd_6708
crossref_primary_10_1007_s41669_021_00261_y
crossref_primary_10_2147_IJWH_S437214
crossref_primary_10_1016_j_ogc_2017_10_004
Cites_doi 10.1136/bmj.c7401
10.1097/01.AOG.0000423819.85283.f4
10.1371/journal.pone.0088484
10.1038/gim.2013.26
10.3109/14767058.2012.722731
10.1186/1755-8794-5-57
10.1002/pd.3946
10.1016/j.ajhg.2012.12.006
10.1002/pd.4076
10.1056/NEJMoa043693
10.1002/pd.3993
10.1002/pd.4126
10.1517/14712598.2012.670632
10.1002/pd.4160
10.1002/uog.13277
10.1002/pd.4139
10.1016/j.ajog.2010.12.060
10.1002/pd.4100
10.1056/NEJMoa1311037
10.1371/journal.pone.0109173
10.1016/j.ajog.2014.08.006
10.3310/hta7110
10.1002/pd.4123
10.1097/AOG.0b013e31824fb482
10.1073/pnas.0808319105
10.1371/journal.pone.0021791
10.1002/uog.12504
10.1002/pd.2637
10.1002/pd.4110
10.1016/j.ajog.2012.01.030
10.1097/AOG.0000000000000363
10.1016/j.ajog.2012.01.029
10.1016/j.ajog.2012.05.021
10.1097/GIM.0b013e3182368a0e
10.1007/s10897-012-9564-0
10.1073/pnas.0810641105
10.1002/pd.4002
10.1038/gim.2011.73
10.1371/journal.pone.0065050
10.1038/gim.2013.126
ContentType Journal Article
Copyright Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd
Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
Copyright_xml – notice: Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd
– notice: Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
8FD
FR3
K9.
P64
7X8
RC3
DOI 10.1002/uog.14792
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
Genetics Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
Genetics Abstracts
DatabaseTitleList MEDLINE - Academic

ProQuest Health & Medical Complete (Alumni)
MEDLINE
CrossRef
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1469-0705
EndPage 538
ExternalDocumentID 3663993211
25598039
10_1002_uog_14792
UOG14792
Genre article
Multicenter Study
Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
123
1L6
1OC
24P
29Q
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5RE
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
ESX
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HF~
HGLYW
HHY
HHZ
HZ~
IHE
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
RYL
SUPJJ
TEORI
UB1
V2E
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
XV2
YFH
ZZTAW
~IA
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGXDD
AGYGG
AIDQK
AIDYY
CITATION
O8X
CGR
CUY
CVF
ECM
EIF
NPM
7QO
8FD
FR3
K9.
P64
7X8
RC3
ID FETCH-LOGICAL-c4872-793eff36daae797a4e538094575e8c1c17eb544243756d6b55e74a0624c7c2d23
IEDL.DBID WIN
ISICitedReferencesCount 282
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000353503000008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0960-7692
1469-0705
IngestDate Tue Oct 07 09:48:51 EDT 2025
Fri Jul 11 15:05:22 EDT 2025
Sat Nov 29 14:29:18 EST 2025
Mon Jul 21 06:04:26 EDT 2025
Tue Nov 18 20:25:56 EST 2025
Sat Nov 29 03:32:15 EST 2025
Wed Jan 22 16:23:36 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords false negative
clinical performance
mosaicism
cell-free DNA
CNV
NIPT
low-risk population
trisomy
false positive
Language English
License Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4872-793eff36daae797a4e538094575e8c1c17eb544243756d6b55e74a0624c7c2d23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/uog.14792
PMID 25598039
PQID 1675123137
PQPubID 1006490
PageCount 9
ParticipantIDs proquest_miscellaneous_1680456296
proquest_miscellaneous_1676595052
proquest_journals_1675123137
pubmed_primary_25598039
crossref_primary_10_1002_uog_14792
crossref_citationtrail_10_1002_uog_14792
wiley_primary_10_1002_uog_14792_UOG14792
PublicationCentury 2000
PublicationDate May 2015
PublicationDateYYYYMMDD 2015-05-01
PublicationDate_xml – month: 05
  year: 2015
  text: May 2015
PublicationDecade 2010
PublicationPlace Chichester, UK
PublicationPlace_xml – name: Chichester, UK
– name: England
– name: London
PublicationTitle Ultrasound in obstetrics & gynecology
PublicationTitleAlternate Ultrasound Obstet Gynecol
PublicationYear 2015
Publisher John Wiley & Sons, Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Ltd
– name: Wiley Subscription Services, Inc
References 2012; 120
2013; 26
2013; 22
2005; 353
2013; 42
2011; 31
2013; 92
2008; 105
2011; 13
2014; 370
2012; 14
2013; 8
2011; 6
2012; 12
2012; 206
2012; 32
2012; 207
2014; 211
2014; 43
2011; 204
2013; 15
2013; 33
2003; 7
2014; 16
2014; 9
2012; 5
2011; 342
2012; 119
2014; 124
e_1_2_6_32_1
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_30_1
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_39_1
e_1_2_6_15_1
e_1_2_6_38_1
e_1_2_6_16_1
e_1_2_6_37_1
e_1_2_6_21_1
e_1_2_6_20_1
e_1_2_6_41_1
e_1_2_6_40_1
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_24_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_22_1
e_1_2_6_29_1
e_1_2_6_28_1
e_1_2_6_27_1
e_1_2_6_26_1
25914392 - Ultrasound Obstet Gynecol. 2015 May;45(5):512-3
26134734 - Ultrasound Obstet Gynecol. 2015 Jul;46(1):130
References_xml – volume: 370
  start-page: 799
  year: 2014
  end-page: 808
  article-title: DNA sequencing versus standard prenatal aneuploidy screening
  publication-title: N Engl J Med
– volume: 33
  start-page: 602
  year: 2013
  end-page: 608
  article-title: Secondary findings from non‐invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service
  publication-title: Prenat Diagn
– volume: 120
  start-page: 1532
  year: 2012
  end-page: 1534
  article-title: Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy
  publication-title: Obstet Gynecol
– volume: 15
  start-page: 729
  year: 2013
  end-page: 732
  article-title: Positive cell‐free fetal DNA testing for trisomy 13 reveals confined placental mosaicism
  publication-title: Genet Med
– volume: 9
  start-page: e88484
  year: 2014
  article-title: Maternal plasma fetal DNA fractions in pregnancies with low and high risks for fetal chromosomal aneuploidies
  publication-title: PLoS One
– volume: 12
  start-page: S19
  issue: Suppl 1
  year: 2012
  end-page: S26
  article-title: Non‐invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing‐by‐ligation and evidence that cell‐free fetal DNA in the maternal plasma originates from cytotrophoblastic cells
  publication-title: Expert Opin Biol Ther
– volume: 206
  start-page: 319.e1
  year: 2012
  end-page: 9
  article-title: Noninvasive prenatal detection and selective analysis of cell‐free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18
  publication-title: Am J Obstet Gynecol
– volume: 26
  start-page: 143
  year: 2013
  end-page: 145
  article-title: The fetal fraction of cell‐free DNA in maternal plasma is not affected by a priori risk of fetal trisomy
  publication-title: J Matern Fetal Neonatal Med
– volume: 211
  start-page: 527.e1
  year: 2014
  end-page: 527.e17
  article-title: Clinical experience and follow‐up with large scale single‐nucleotide polymorphism‐based noninvasive prenatal aneuploidy testing
  publication-title: Am J Obstet Gynecol
– volume: 43
  start-page: 254
  year: 2014
  end-page: 264
  article-title: Non‐invasive prenatal testing for fetal chromosomal abnormalities by low‐coverage whole‐genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center
  publication-title: Ultrasound Obstet Gynecol
– volume: 353
  start-page: 2001
  year: 2005
  end-page: 2011
  article-title: First‐trimester or second‐trimester screening, or both, for Down's syndrome
  publication-title: N Engl J Med
– volume: 105
  start-page: 16 266
  year: 2008
  end-page: 16 271
  article-title: Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood
  publication-title: Proc Natl Acad Sci USA
– volume: 13
  start-page: 913
  year: 2011
  end-page: 920
  article-title: DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study
  publication-title: Genet Med
– volume: 342
  start-page: c7401
  year: 2011
  article-title: Non‐invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study
  publication-title: BMJ
– volume: 16
  start-page: 281
  year: 2014
  end-page: 285
  article-title: Noninvasive prenatal testing: limitations and unanswered questions
  publication-title: Genet Med
– volume: 206
  start-page: 322.e1
  year: 2012
  end-page: 5
  article-title: Chromosome‐selective sequencing of maternal plasma cell‐free DNA for first‐trimester detection of trisomy 21 and trisomy 18
  publication-title: Am J Obstet Gynecol
– volume: 207
  start-page: 137.e1
  year: 2012
  end-page: 8
  article-title: Non‐Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18
  publication-title: Am J Obstet Gynecol
– volume: 32
  start-page: 1114
  year: 2012
  end-page: 1116
  article-title: Noninvasive prenatal genetic testing for fetal aneuploidy detects maternal trisomy X
  publication-title: Prenat Diagn
– volume: 7
  start-page: 1
  year: 2003
  end-page: 77
  article-title: First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS)
  publication-title: Health Technol Assess
– volume: 33
  start-page: 700
  year: 2013
  end-page: 706
  article-title: Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population
  publication-title: Prenat Diagn
– volume: 119
  start-page: 890
  year: 2012
  end-page: 901
  article-title: Genome‐wide fetal aneuploidy detection by maternal plasma DNA sequencing
  publication-title: Obstet Gynecol
– volume: 33
  start-page: 609
  year: 2013
  end-page: 611
  article-title: Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease
  publication-title: Prenat Diagn
– volume: 105
  start-page: 20 458
  year: 2008
  end-page: 20 463
  article-title: Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma
  publication-title: Proc Natl Acad Sci USA
– volume: 6
  start-page: e21791
  year: 2011
  article-title: Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing
  publication-title: PLoS One
– volume: 14
  start-page: 296
  year: 2012
  end-page: 305
  article-title: DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study
  publication-title: Genet Med
– volume: 33
  start-page: 569
  year: 2013
  end-page: 574
  article-title: Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples
  publication-title: Prenat Diagn
– volume: 5
  start-page: 57
  year: 2012
  article-title: Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies
  publication-title: BMC Med Genomics
– volume: 42
  start-page: 34
  year: 2013
  end-page: 40
  article-title: Implementation of maternal blood cell‐free DNA testing in early screening for aneuploidies
  publication-title: Ultrasound Obstet Gynecol
– volume: 32
  start-page: 1233
  year: 2012
  end-page: 1241
  article-title: Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci
  publication-title: Prenat Diagn
– volume: 33
  start-page: 584
  year: 2013
  end-page: 590
  article-title: A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing
  publication-title: Prenat Diagn
– volume: 124
  start-page: 210
  year: 2014
  end-page: 218
  article-title: Single‐nucleotide polymorphism‐based noninvasive prenatal screening in a high‐risk and low‐risk cohort
  publication-title: Obstet Gynecol
– volume: 92
  start-page: 167
  year: 2013
  end-page: 176
  article-title: Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma
  publication-title: Am J Hum Genet
– volume: 22
  start-page: 291
  year: 2013
  end-page: 295
  article-title: Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors
  publication-title: J Genet Couns
– volume: 204
  start-page: 205.e1
  year: 2011
  end-page: 11
  article-title: Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting
  publication-title: Am J Obstet Gynecol
– volume: 32
  start-page: 1225
  year: 2012
  end-page: 1232
  article-title: Clinical application of massively parallel sequencing‐based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors
  publication-title: Prenat Diagn
– volume: 33
  start-page: 622
  year: 2013
  end-page: 629
  article-title: Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis
  publication-title: Prenat Diagn
– volume: 8
  start-page: e65050
  year: 2013
  article-title: Effective noninvasive zygosity determination by maternal plasma target region sequencing
  publication-title: PLoS One
– volume: 9
  start-page: e109173
  year: 2014
  article-title: Non‐invasive prenatal chromosomal aneuploidy testing – clinical experience: 100,000 clinical samples
  publication-title: PLoS One
– volume: 31
  start-page: 7
  year: 2011
  end-page: 15
  article-title: Screening for fetal aneuploidies at 11 to 13 weeks
  publication-title: Prenat Diagn
– volume: 33
  start-page: 667
  year: 2013
  end-page: 674
  article-title: The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies
  publication-title: Prenat Diagn
– ident: e_1_2_6_7_1
  doi: 10.1136/bmj.c7401
– ident: e_1_2_6_17_1
  doi: 10.1097/01.AOG.0000423819.85283.f4
– ident: e_1_2_6_31_1
  doi: 10.1371/journal.pone.0088484
– ident: e_1_2_6_35_1
  doi: 10.1038/gim.2013.26
– ident: e_1_2_6_32_1
  doi: 10.3109/14767058.2012.722731
– ident: e_1_2_6_14_1
  doi: 10.1186/1755-8794-5-57
– ident: e_1_2_6_34_1
  doi: 10.1002/pd.3946
– ident: e_1_2_6_39_1
  doi: 10.1016/j.ajhg.2012.12.006
– ident: e_1_2_6_40_1
  doi: 10.1002/pd.4076
– ident: e_1_2_6_2_1
  doi: 10.1056/NEJMoa043693
– ident: e_1_2_6_15_1
  doi: 10.1002/pd.3993
– ident: e_1_2_6_33_1
  doi: 10.1002/pd.4126
– ident: e_1_2_6_36_1
  doi: 10.1517/14712598.2012.670632
– ident: e_1_2_6_19_1
  doi: 10.1002/pd.4160
– ident: e_1_2_6_37_1
  doi: 10.1002/uog.13277
– ident: e_1_2_6_18_1
  doi: 10.1002/pd.4139
– ident: e_1_2_6_9_1
  doi: 10.1016/j.ajog.2010.12.060
– ident: e_1_2_6_41_1
  doi: 10.1002/pd.4100
– ident: e_1_2_6_22_1
  doi: 10.1056/NEJMoa1311037
– ident: e_1_2_6_27_1
  doi: 10.1371/journal.pone.0109173
– ident: e_1_2_6_26_1
  doi: 10.1016/j.ajog.2014.08.006
– ident: e_1_2_6_3_1
  doi: 10.3310/hta7110
– ident: e_1_2_6_38_1
  doi: 10.1002/pd.4123
– ident: e_1_2_6_13_1
  doi: 10.1097/AOG.0b013e31824fb482
– ident: e_1_2_6_5_1
  doi: 10.1073/pnas.0808319105
– ident: e_1_2_6_8_1
  doi: 10.1371/journal.pone.0021791
– ident: e_1_2_6_20_1
  doi: 10.1002/uog.12504
– ident: e_1_2_6_4_1
  doi: 10.1002/pd.2637
– ident: e_1_2_6_23_1
  doi: 10.1002/pd.4110
– ident: e_1_2_6_28_1
  doi: 10.1016/j.ajog.2012.01.030
– ident: e_1_2_6_30_1
  doi: 10.1097/AOG.0000000000000363
– ident: e_1_2_6_12_1
  doi: 10.1016/j.ajog.2012.01.029
– ident: e_1_2_6_29_1
  doi: 10.1016/j.ajog.2012.05.021
– ident: e_1_2_6_10_1
  doi: 10.1097/GIM.0b013e3182368a0e
– ident: e_1_2_6_16_1
  doi: 10.1007/s10897-012-9564-0
– ident: e_1_2_6_6_1
  doi: 10.1073/pnas.0810641105
– ident: e_1_2_6_21_1
  doi: 10.1002/pd.4002
– ident: e_1_2_6_11_1
  doi: 10.1038/gim.2011.73
– ident: e_1_2_6_24_1
  doi: 10.1371/journal.pone.0065050
– ident: e_1_2_6_25_1
  doi: 10.1038/gim.2013.126
– reference: 26134734 - Ultrasound Obstet Gynecol. 2015 Jul;46(1):130
– reference: 25914392 - Ultrasound Obstet Gynecol. 2015 May;45(5):512-3
SSID ssj0006436
Score 2.596253
Snippet ABSTRACT Objectives To report the clinical performance of massively parallel sequencing‐based non‐invasive prenatal testing (NIPT) in detecting trisomies 21,...
Linked Comment: Ultrasound Obstet Gynecol 2015; 45: 512–513
To report the clinical performance of massively parallel sequencing-based non-invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over...
Objectives To report the clinical performance of massively parallel sequencing-based non-invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 530
SubjectTerms Adult
Cell-Free System
cell‐free DNA
China - epidemiology
Chromosome Disorders - diagnosis
Chromosome Disorders - embryology
Chromosome Disorders - genetics
Chromosomes, Human, Pair 13 - genetics
Chromosomes, Human, Pair 18 - genetics
clinical performance
CNV
DNA - genetics
DNA Methylation
Down Syndrome - diagnosis
Down Syndrome - embryology
Down Syndrome - genetics
false negative
false positive
Female
Follow-Up Studies
Genetic Testing - methods
Humans
Infant, Newborn
low‐risk population
Maternal Serum Screening Tests
mosaicism
NIPT
Pregnancy
Pregnancy Outcome
Prenatal Diagnosis
Reproducibility of Results
trisomy
Trisomy - diagnosis
Trisomy - genetics
Trisomy 13 Syndrome
Trisomy 18 Syndrome
Title Non‐invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146 958 pregnancies
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fuog.14792
https://www.ncbi.nlm.nih.gov/pubmed/25598039
https://www.proquest.com/docview/1675123137
https://www.proquest.com/docview/1676595052
https://www.proquest.com/docview/1680456296
Volume 45
WOSCitedRecordID wos000353503000008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Free Content
  customDbUrl:
  eissn: 1469-0705
  dateEnd: 20241212
  omitProxy: false
  ssIdentifier: ssj0006436
  issn: 0960-7692
  databaseCode: WIN
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
– providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1469-0705
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0006436
  issn: 0960-7692
  databaseCode: DRFUL
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB4tC0JceC8UlsogDhyINn4ncEJAAWkpCFHoLbIdu6q0m6Jtu2d-Ar-RX8LYeaAVDyFxi5RJ5Dj-Zr7x4xuAh9Sp3Msgs0CtzYR0RWaMqzMZnJCYPtc-HY_-dKin02I-L9_vwNP-LEyrDzFMuEVkJH8dAW7s-uCnaOh2tUCY6zL6XyoSKD-_mQ5eGCNtWqdEhp5pVbJeVShnB8OTZ2PRLwTzLF9NAWdy5b-aehUudzyTPGsHxjXY8c11uPi2W0m_Acvpqvn-9duyOTVxAzuJ0pZxJodsouxGsyBIZskmFig8xlyaMPqY0IKYpiaUPyH9eUriB6VkEg-qEPSIpJRFfN2iLfy7vgmzycuPz19nXdmFzGH2gny75D4ErmpjvC61ER6dImaBSOx84aij2lspRFQylKpWVkqvhckVE047VjO-B7vNqvG3gUgbuLCKW664qANyMRYwIZNcIuxzG0bwqP8Bles0yWNpjKOqVVNmFXZdlbpuBA8G0y-tEMfvjPb7v1h1WFxXFHMijM-U6xHcH24jiuLSiGn8aptsorBiLtnfbIqUL5ZqBLfaETK0JOnc57zED0oD4c9NrGbvXqWLO_9uehcuIU-T7T7LfdjdnGz9PbjgTjfL9ckYzul5MYbzLz5MZofjhIIfAu0Fhg
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5VWwRcyrOwbQGDOHAgavxOEBcELEVsF4S6qLfIcezVSm0WdXd75ifwG_klHTsPVPEQErdImUSOPY9v7Mw3AE-pVamTXiaelmUipM0SY2yVSG-FxPS5crE8-stYTybZ8XH-aQNedrUwDT9Ev-EWLCP662DgYUN6_ydr6HoxQzvXOTrgTYFqJAew-ebzaDruPTFG23hWiSg90SpnHbNQyvb7hy_Ho19A5mXMGoPO6Mb_DfcmbLVgk7xqtOMWbLj6Nlw9bI_T78B8sqh_fPs-r89N-IudBH7LsJ1DVoF7o54RRLRkFboUnmJCTRh9TmhGTF0Ryl-QrqiSuJ4umYRqFYJukeQyC6-bNd1_l3dhOnp79PogaXsvJBZTGATdOXfec1UZ43SujXDoGTEVRHTnMkst1a6UQgQ6Q6kqVUrptDCpYsJqyyrGt2FQL2p3H4gsPRel4iVXXFQeARnzmJVJLnHR0tIP4Vm3AoVticlDf4yToqFUZgVOXRGnbghPetGvDRvH74T2umUsWoNcFhQTIwzSlOshPO5voymF8xFTu8U6ygR2xVSyv8lkMWnM1RDuNSrSjySS3ac8xw-KmvDnIRbTj-_ixc6_iz6CawdHh-Ni_H7yYReuI3CTzY-XezBYna3dA7hiz1fz5dnD1gwuAC86CEo
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5VLaq48KYsFDCIAweixu8YcUGUBcSyVIhFvUWOY69WgmzV3e2Zn8Bv5Jcwdh6o4iEkbpEyiRzH38w3fnwD8Ig6lXsZZBZoVWVCuiKz1tWZDE5ITJ9rn45Hf5ro6bQ4PjZHW_CsPwvT6kMME24RGclfR4D7kzoc_FQN3SzniHNt0AHvCGkUwnLn8MN4Nhk8MUbbtFaJLD3TyrBeWShnB8PD5-PRLyTzPGdNQWd8-f-aewUudWSTPG9Hx1XY8s012H3XLadfh8V02Xz_-m3RnNm4i51Efcs4nUPWUXujmRNktGQdqxR-wYSaMPqE0ILYpiaUPyX9oUriB7lkEk-rEHSLxMgivm7eVv9d3YDZ-OXHF6-zrvZC5jCFQdJtuA-Bq9par422wqNnxFQQ2Z0vHHVU-0oKEeUMpapVJaXXwuaKCacdqxm_CdvNsvG3gMgqcFEpXnHFRR2QkLGAWZnkErGfV2EEj_s_ULpOmDzWx_hctpLKrMSuK1PXjeDhYHrSqnH8zmi__41lB8hVSTExwiBNuR7Bg-E2Qimuj9jGLzfJJqor5pL9zaZISaNRI9hrh8jQkiR2n3ODH5RGwp-bWM7ev0oXt__d9D7sHh2Oy8mb6ds7cBF5m2z3Xe7D9vp04-_CBXe2XqxO73Uo-AGtUAfF
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Non%E2%80%90invasive+prenatal+testing+for+trisomies+21%2C+18+and+13%3A+clinical+experience+from+146+958+pregnancies&rft.jtitle=Ultrasound+in+obstetrics+%26+gynecology&rft.au=Zhang%2C+H.&rft.au=Gao%2C+Y.&rft.au=Jiang%2C+F.&rft.au=Fu%2C+M.&rft.date=2015-05-01&rft.pub=John+Wiley+%26+Sons%2C+Ltd&rft.issn=0960-7692&rft.eissn=1469-0705&rft.volume=45&rft.issue=5&rft.spage=530&rft.epage=538&rft_id=info:doi/10.1002%2Fuog.14792&rft.externalDBID=10.1002%252Fuog.14792&rft.externalDocID=UOG14792
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0960-7692&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0960-7692&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0960-7692&client=summon